Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
5.2M
-
Shares change
-
-1.3M
-
Total reported value, excl. options
-
$52.6M
-
Value change
-
-$3.66M
-
Number of buys
-
19
-
Number of sells
-
-12
-
Price
-
$10.14
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q4 2020
40 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q4 2020.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.2M shares
of 51.9M outstanding shares and own 10.01% of the company stock.
Largest 10 shareholders include Stonepine Capital Management, LLC (950K shares), Corriente Advisors, LLC (807K shares), Point72 Asset Management, L.P. (800K shares), Manatuck Hill Partners, LLC (572K shares), Granite Point Capital Management, L.P. (547K shares), Ikarian Capital, LLC (415K shares), JACOB ASSET MANAGEMENT OF NEW YORK LLC (140K shares), NORTHERN TRUST CORP (121K shares), RENAISSANCE TECHNOLOGIES LLC (113K shares), and EAM Investors, LLC (110K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.